Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 78
Filtrar
1.
Prog Urol ; 24(2): 87-93, 2014 Feb.
Artículo en Francés | MEDLINE | ID: mdl-24485077

RESUMEN

OBJECTIVE: Our study aimed to support the viability of the concept of Ipsilateral Dual Kidney Transplantation (DKT) by presenting our initial experience and proposing a review of the literature in this subject. METHODS: Fifteen ipsilateral DKT were performed at Nice University Hospital between August 2010 and March 2012. We have described our skin incision preferences, the vascular anastomoses, and the uretero-vesical reimplantation. We have analyzed the operative duration, the cold ischemia time (CIT) of both transplants, the blood transfusion volume, the intraoperative and postoperative complications, the time to diuresis recovery, the hospital stay, and the kinetics of the creatinine clearance until the third postoperative month. We have compared our results with those of the literature. RESULTS: The average CIT of the first transplant (T1) was 17.5 ± 3.3 hours, and that of the second (T2) was 18.4 ± 3.3 hours. The mean operating time was 234 ± 67 minutes. Patients received an average of 2 units of blood during surgery [0-4] and 1.8 units in the postoperative period [0-15]. The complications rate was 26.7% and included an intraoperative T2 artery thrombosis and 3 postoperative complications consistent with a hematoma, a T2 ureteric necrosis and a T2 venous thrombosis. Two transplants were lost (6.7%) and one death (6.7%) was reported on day 40. The average length of hospital stay was 20.9 ± 7.8 days. The mean creatinine clearance values were 12.6 mL/min at D2, 35.6 mL/min at D7, 44.9 mL/min on discharge, and 48.2 mL/min at D90. CONCLUSION: Our results supported the viability of the dual kidney transplantation concept. Furthermore the ipsilateral approach shortened the procedure and limited the surgical trauma by preserving the contralateral iliac fossa, without compromising renal function recovery or increasing morbidity.


Asunto(s)
Trasplante de Riñón/métodos , Anciano , Femenino , Humanos , Masculino
2.
J Small Anim Pract ; 48(12): 670-6, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17725589

RESUMEN

OBJECTIVES: To determine if ketamine administered to bitches at the end of a mastectomy, followed by a six-hour constant rate infusion (CRI), improved postoperative opioid analgesia and feeding behaviour. METHODS: The bitches were randomised into three groups: the placebo group received 0.09 ml/kg isotonic saline intravenously followed by a six-hour CRI of 0.5 ml/kg/hour, the low-dose ketamine received 150 microg/kg ketamine intravenously followed by a six-hour CRI of 2 microg/kg/minute and the high-dose ketamine group received 700 microg/kg ketamine intravenously followed by a six-hour CRI of 10 microg/kg/minute. Any additional opioids given were recorded at the time of extubation and at intervals after extubation. Food intake was evaluated eight (T8) and 20 (T20) hours after extubation by measuring the per cent coverage of basal energy requirements (BER). RESULTS: No significant difference was observed for opioid requirements between the three groups. The mean percentages of BER coverage did not differ significantly at T8 but the difference between the high-dose and low-dose ketamine groups (P=0.014), and the high-dose ketamine and placebo groups (P=0.038) was significant at T20. CLINICAL SIGNIFICANCE: This study demonstrated that 700 microg/kg ketamine given intravenously postoperatively followed by a six-hour ketamine CRI of 10 microg/kg/minute improved patient feeding behaviour.


Asunto(s)
Anestésicos Disociativos/uso terapéutico , Enfermedades de los Perros/cirugía , Conducta Alimentaria , Ketamina/uso terapéutico , Mastectomía/veterinaria , Dolor Postoperatorio/veterinaria , Anestésicos Disociativos/administración & dosificación , Animales , Enfermedades de los Perros/patología , Perros , Femenino , Infusiones Intravenosas/veterinaria , Ketamina/administración & dosificación , Neoplasias Mamarias Animales/patología , Neoplasias Mamarias Animales/cirugía , Dimensión del Dolor/veterinaria , Dolor Postoperatorio/prevención & control , Resultado del Tratamiento
3.
Leuk Lymphoma ; 44(5): 889-90, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12802933

RESUMEN

Rituximab (chimeric anti-CD20 IgG1 monoclonal antibody) is effective in the treatment of relapsed/refractory low-grade lymphomas of B-cell origin as well as in diffuse large B-cell lymphoma. Several reports also demonstrated the efficacy of rituximab for the treatment of autoimmune cytopenia, especially for cold agglutinin disease. We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia. The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab.


Asunto(s)
Anemia Hemolítica Autoinmune/inducido químicamente , Anticuerpos Monoclonales/efectos adversos , Trastornos Linfoproliferativos/complicaciones , Anemia Hemolítica Autoinmune/etiología , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales de Origen Murino , Transformación Celular Neoplásica , Progresión de la Enfermedad , Humanos , Inmunoglobulina M , Leucemia Linfocítica Crónica de Células B/complicaciones , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Trastornos Linfoproliferativos/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Rituximab , Esplenomegalia
4.
Leuk Lymphoma ; 44(4): 619-26, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12769338

RESUMEN

Numerous studies have demonstrated efficacy of imipenem-cilastatin, 50 mg/kg/day, as first line therapy in febrile patients with neutropenia of short duration consecutive to cytostatic chemotherapy. However, only two studies used low dosage of this antibiotic as 1.5 g/day, in prospective, double blind, randomized clinical trials, in this indication. Efficacy and tolerability of imipenem-cilastatin 0.5 g three times daily IV in 30-min infusions, as first-line empiric therapy, were retrospectively evaluated in our hematological unit. From January 1996 to September 2000, 30 neutropenic patients (12 females) with 45 febrile episodes were included. Median age was 57.5 years (31-75). Twenty-four of them had lymphomas, 4 solid tumors and 2 myelomas. There were 13 clinically documented infections, (CD, 28.8%), 16 microbiologically documented infections, (MD, 35.6%) and 16 febrile episodes corresponding to fever of unknown origin, (FUO, 35.6%). The median neutrophils count on nadir (n = 44), was 67/mm3 (8-369). The median duration of neutropenia was 5 days (3-15). Bacteremia was observed in 10 patients, urinary tract infection in 3 patients. The most frequently isolated microorganism was Escherichia coli. The overall success rate of the first line therapy was 66.7%. Adverse events were observed in 11.1% of the patients without necessity to stop treatment. The MD infections showed a lower rate of success compared with CD infections and FUO. These data were in accordance with the previous studies. The importance of number of microorganisms (p = 0.007) and of infected sites (p = 0.01) appeared as prognostic factors (univariate analysis). Although imipenem-cilastatin has been used in numerous studies as empiric broad-spectrum antibiotic therapy in the treatment of febrile neutropenic cancer patients, the exact dosage of this antibiotic is still not standardized. However, utilization of this antibiotic in monotherapy at low dosage seems to us to be safe and effective as usual dosage in the antimicrobial treatment ofthe febrile patients with post chemotherapy neutropenia of short duration.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/tratamiento farmacológico , Imipenem/administración & dosificación , Imipenem/uso terapéutico , Neutropenia/tratamiento farmacológico , Adulto , Anciano , Escherichia coli/metabolismo , Femenino , Neoplasias Hematológicas/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Neutropenia/microbiología , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento
5.
Int J Oncol ; 21(4): 901-6, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12239633

RESUMEN

1,25-dihydroxycholecalciferol [1,25-(OH)2 D3] has been shown to have antiproliferative effects in a wide variety of cancer cell lines. In vivo studies, although often limited by the development of hypercalcemia, have also shown the potential usefulness of 1,25-(OH)2 D3 in inhibiting tumor growth. The potential usefulness of the drug has been hampered by the development of hypercalcemia. This pilot clinical study was designed to evaluate the preclinical results that have shown, locoregional administration of 1,25-(OH)2 D3 in lipiodol can prevent the development of hypercalcemia. Eight patients with refractory HCC were given a single intrahepatic arterial dose (50, 75 or 100 microg) of 1,25-(OH)2 D3 dissolved in 5 ml of lipiodol. Following this, for 4 weeks serum calcium, 1,25-(OH)2 D3, alpha-fetoprotein and a range of biochemical indices were monitored. While, in 3 patients the calcium levels exceeded the normal range, even at these extremely high doses, non of the patients developed grade 3 hypercalcemia. 1,25-(OH)2 D3 administration also led to transient stabilization of serum alpha-fetoprotein in these patients. The data obtained support the hypothesis that, in patients with HCC, locoregional delivery of 1,25-(OH)2 D3 in lipiodol can allow administration of supra-pharmacological doses of the drug without the development of hypercalcemia.


Asunto(s)
Calcitriol/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Aceite Yodado/farmacología , Neoplasias Hepáticas/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Calcio/metabolismo , Agonistas de los Canales de Calcio/uso terapéutico , División Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inyecciones Intraarteriales , Masculino , Persona de Mediana Edad , Proyectos Piloto , Factores de Tiempo , alfa-Fetoproteínas/metabolismo
6.
Acta Chir Belg ; 102(2): 110-3, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12051082

RESUMEN

OBJECTIVE: To evaluate the possibility and accuracy of this new diagnostic approach to the breast cancer disease in our centre. MATERIAL AND METHODS: Since March 1999, every patient presenting with a cT1-T2 N0 breast carcinoma was scheduled for a sentinel lymph node search. An injection of Tc-99 labelled nanocolloïd with a dose of 1 mCu was injected either intramammary or intradermally. The patients have been divided into two groups: in group I, they received their injection intramammarily the day before the operation; because of several failures in identifying the sentinel lymph node (SLN), the protocol was modified, the patients receiving their injection the day of operation, intradermally (group II). Once a lymphoscintigraphy done, the SLN was identified at operation using a detection probe, after the primary tumour had been removed. A routine axillary dissection was then performed to remove the rest of the lymph nodes. All the nodes were then checked routinely for metastatic cells. The SLN was also screened by semi-serial slides and by immuno-assay. RESULTS: From March 1999 till March 2001, sixty patients presented consecutively with a T1 or T2 biopsy proven breast carcinoma with no clinical lymph nodes. They were all scheduled for a sentinel lymph node search according to the protocol. Mean tumour size was 9.9 mm (ranging from 4 to 23 mm). Fourteen patients (group I) received their injection intramammarily but we failed to identify the sentinel node in five patients (35%). The remaining forty-two patients (group II) received their injection intradermally. Sentinel nodes were then identified in forty-three patients (93%). Positive SLN were discovered in eleven cases by routine examination (13 positive nodes among 104 harvested sentinel nodes, i.e. 13%). Micro metastases were discovered in three other SLN by immunohistology. In total, 605 lymph nodes were evaluated through the axillary dissection, representing a mean number of 10.08 lymph nodes per patient. For four patients, positive lymph node were discovered in the axillary dissection while SLN were negative (6.6% of false negative). CONCLUSIONS: During this learning curve period, it appears that the method for screening the SLN is reliable, since the figures encountered are similar to those of the literature. By adding a perioperative blue dye injection, it might be possible to reduce the percentage of false negative results. It is difficult to assess, at present, the impact SLN could have on survival.


Asunto(s)
Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/diagnóstico por imagen , Carcinoma Ductal de Mama/cirugía , Carcinoma Lobular/diagnóstico por imagen , Carcinoma Lobular/cirugía , Biopsia del Ganglio Linfático Centinela/métodos , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/patología , Carcinoma Lobular/patología , Estudios de Factibilidad , Femenino , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Cintigrafía , Reproducibilidad de los Resultados
7.
Arch Surg ; 136(10): 1154-7, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11585508

RESUMEN

HYPOTHESIS: The usefulness of additional edge cryotherapy after liver resection for liver metastases from colorectal cancer to improve involved or inadequate (less than 1 cm) margins is uncertain. DESIGN: Retrospective analysis of prospectively collected data. SETTING: Department of surgery at a university hospital. PATIENTS: Eighty-six consecutive patients with hepatic metastases from colorectal cancer in whom we applied additional edge cryotherapy to involved or inadequate margins. This group was compared with 134 patients who underwent resection without edge cryotherapy (control group) during the same period. INTERVENTION: Potentially curative treatment was achieved by adding edge cryotherapy to insufficient resection sites in patients not eligible for further resection. MAIN OUTCOME MEASURES: Edge recurrence rate in the study group; validation of an additional treatment to improve curative resectability; and comparison of morbidity and local recurrence rates with the control group. RESULTS: At a median follow-up of 39 months, 47 patients were alive and 39 had died. Local recurrence at the resection site was diagnosed in 9 patients (10%), of which 7 occurred in patients with involved margins and 2 in patients with resection margin less than 1 cm. Thirty-six patients (42%) experienced recurrence in the remnant liver. Extrahepatic recurrence occurred in 38 patients (44%), the lungs being the most common site (22 patients [26%]). CONCLUSIONS: Edge cryotherapy is a potent additional surgical treatment option in patients with liver metastases from colorectal cancer. The percentage of patients who can be treated for cure can be increased, especially if complex liver surgery is demanded.


Asunto(s)
Neoplasias Colorrectales/patología , Criocirugía , Hepatectomía , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Recurrencia Local de Neoplasia , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Neoplasias Hepáticas/mortalidad , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia
8.
Oncology ; 61(1): 42-6, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11474247

RESUMEN

Our preclinical studies have shown that the widely used antiparasitic drug albendazole has potent antiproliferative activity against colorectal cancer (CRC) and hepatocellular carcinoma (HCC). This trial was designed to evaluate albendazole in a small number of patients (n = 7) with either HCC or CRC and hepatic metastases refractory to other forms of therapy. Albendazole was given at 10 mg/kg/day orally in two divided doses for a period of 28 days. To follow the effect of treatment, tumor markers, carcinoembryonic antigen (CEA) or alpha-feto protein (AFP), were measured routinely in these patients. A range of hematological and biochemical indices were also serially measured to monitor bone marrow, kidney or liver toxicity. Albendazole therapy resulted in a decrease in CEA in 2 patients. In the remaining 5 with measurable tumor markers, serum CEA or AFP was stabilized in 3 patients, while in the other 2, after an initial stabilization (5-10 days), the markers began to increase. In the 7 patients completing the trial, albendazole was well tolerated and there were no significant changes in any hematological, kidney or liver function tests, but 3 patients were withdrawn for severe neutropenia which was probably contributory to the death of 1 patient. These data support our previous experimental results demonstrating that albendazole has antitumor effects.


Asunto(s)
Albendazol/uso terapéutico , Antineoplásicos/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Adulto , Anciano , Albendazol/administración & dosificación , Albendazol/efectos adversos , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Biomarcadores de Tumor/sangre , Recuento de Células Sanguíneas , Antígeno Carcinoembrionario/sangre , Carcinoma Hepatocelular/sangre , Carcinoma Hepatocelular/patología , Neoplasias Colorrectales/sangre , Neoplasias Colorrectales/patología , Esquema de Medicación , Femenino , Humanos , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/patología , Masculino , Persona de Mediana Edad , Proyectos Piloto , Resultado del Tratamiento
10.
J Biol Chem ; 276(2): 1585-93, 2001 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-11042168

RESUMEN

AGS3 (activator of G-protein signaling 3) was isolated in a yeast-based functional screen for receptor-independent activators of heterotrimeric G-proteins. As an initial approach to define the role of AGS3 in mammalian signal processing, we defined the AGS3 subdomains involved in G-protein interaction, its selectivity for G-proteins, and its influence on the activation state of G-protein. Immunoblot analysis with AGS3 antisera indicated expression in rat brain, the neuronal-like cell lines PC12 and NG108-15, as well as the smooth muscle cell line DDT(1)-MF2. Immunofluorescence studies and confocal imaging indicated that AGS3 was predominantly cytoplasmic and enriched in microdomains of the cell. AGS3 coimmunoprecipitated with Galpha(i3) from cell and tissue lysates, indicating that a subpopulation of AGS3 and Galpha(i) exist as a complex in the cell. The coimmunoprecipitation of AGS3 and Galpha(i) was dependent upon the conformation of Galpha(i3) (GDP GTPgammaS (guanosine 5'-3-O-(thio)triphosphate)). The regions of AGS3 that bound Galpha(i) were localized to four amino acid repeats (G-protein regulatory motif (GPR)) in the carboxyl terminus (Pro(463)-Ser(650)), each of which were capable of binding Galpha(i). AGS3-GPR domains selectively interacted with Galpha(i) in tissue and cell lysates and with purified Galpha(i)/Galpha(t). Subsequent experiments with purified Galpha(i2) and Galpha(i3) indicated that the carboxyl-terminal region containing the four GPR motifs actually bound more than one Galpha(i) subunit at the same time. The AGS3-GPR domains effectively competed with Gbetagamma for binding to Galpha(t(GDP)) and blocked GTPgammaS binding to Galpha(i1). AGS3 and related proteins provide unexpected mechanisms for coordination of G-protein signaling pathways.


Asunto(s)
Proteínas Portadoras/metabolismo , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/metabolismo , Proteínas de Unión al GTP Heterotriméricas/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Encéfalo/metabolismo , Proteínas Portadoras/química , Proteínas Portadoras/genética , Línea Celular , Drosophila melanogaster , Humanos , Datos de Secuencia Molecular , Músculo Liso/metabolismo , Neuronas/metabolismo , Células PC12 , Ratas , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Alineación de Secuencia , Homología de Secuencia de Aminoácido
11.
J Heart Valve Dis ; 10(6): 784-8, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11767187

RESUMEN

Traumatic aortic insufficiency is a rare occurrence after blunt chest trauma, and requires surgical treatment. Aortic valve replacement has been proposed as the procedure of choice, but primary valve repair is being performed increasingly more often. In a plead for conservative surgery, we report a case of valvuloplasty that was controlled by intraoperative aortic endoscopy. When operative conditions permit aortic valve repair, this should be carried out in order to avoid aortic valve replacement and its potential complications, especially in young patients with healthy valves. Replacement is the safest treatment for complex or multiple injuries of the aortic valve, however.


Asunto(s)
Insuficiencia de la Válvula Aórtica/etiología , Insuficiencia de la Válvula Aórtica/cirugía , Válvula Aórtica/lesiones , Válvula Aórtica/cirugía , Endoscopía , Heridas no Penetrantes/complicaciones , Heridas no Penetrantes/cirugía , Accidentes de Tránsito , Adolescente , Válvula Aórtica/patología , Insuficiencia de la Válvula Aórtica/patología , Femenino , Humanos , Heridas no Penetrantes/patología
12.
Arch Surg ; 135(11): 1285-90, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11074882

RESUMEN

HYPOTHESIS: Intraoperative echogenic appearance of liver metastases from colorectal cancer is a prognostic factor of outcome after curative treatment. DESIGN: Retrospective analysis of prospectively collected data. SETTING: Department of Surgery at a university hospital. PATIENTS: One hundred forty-three consecutive patients with hepatic metastases from colorectal cancer who underwent liver resection with curative intent between 1992 and 1998. INTERVENTION: Curative treatment was achieved by liver resection alone, liver resection plus edge cryotherapy, or liver resection plus cryotherapy to lesions not amenable to further resection. In patients with more than 2 lesions, a hepatic artery catheter was placed for regional chemotherapy. MAIN OUTCOME MEASURES: The echogenic appearance of the liver metastases was assessed by intraoperative ultrasound by a single person throughout the study using a 5-MHz ultrasound probe. The findings were prospectively entered into the database. RESULTS: Fifty-four percent of patients had hyperechoic metastases. This group had significantly longer overall (log rank, P<.001) and recurrence-free survival (log rank, P =.004) compared with patients who had hypoechoic metastases (36%). A significantly higher percentage of mucin-secreting tumors were found in the hypoechoic patient group (chi(2), P =.001). Dukes stage of the primary tumor (P =.02), echogenicity of the liver secondaries (P =.04), and diameter of the largest resected metastasis (P =.01) were independent prognostic factors for recurrence-free survival in the Cox regression model. CONCLUSION: These results support the hypothesis that echogenicity of liver metastases from colorectal cancer is an independent prognostic factor of outcome after curative resection.


Asunto(s)
Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/secundario , Neoplasias Colorrectales/patología , Crioterapia , Femenino , Hepatectomía , Humanos , Cuidados Intraoperatorios , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Pronóstico , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Estudios Retrospectivos , Análisis de Supervivencia , Resultado del Tratamiento , Ultrasonografía
13.
Eur Radiol ; 10(10): 1547-9, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11044922

RESUMEN

Pseudomembranous aspergillus bronchitis is considered as an early form of invasive pulmonary aspergillosis, a well-known airway infection in immunocompromised patients. Radiologic features concerning invasive aspergillosis of the airways have been reported. However, we describe here an unusual feature of invasive aspergillus bronchitis, never reported to date, observed in a double-lung transplanted patient. Chest radiograph and CT revealed significant peribronchial thickening without any parenchymal involvement.


Asunto(s)
Aspergilosis/diagnóstico por imagen , Bronquitis/diagnóstico por imagen , Trasplante de Pulmón/efectos adversos , Tomografía Computarizada por Rayos X , Adulto , Aspergilosis/etiología , Aspergilosis/inmunología , Aspergillus fumigatus/aislamiento & purificación , Bronquios/microbiología , Bronquios/patología , Bronquitis/etiología , Bronquitis/inmunología , Líquido del Lavado Bronquioalveolar/microbiología , Broncoscopía , Diagnóstico Diferencial , Resultado Fatal , Femenino , Humanos , Huésped Inmunocomprometido/inmunología , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/cirugía , Linfangioleiomiomatosis/inmunología , Linfangioleiomiomatosis/cirugía
14.
Anticancer Res ; 20(4): 2739-44, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10953352

RESUMEN

BACKGROUND: 1,25-(OH)2 D3 has an in vitro growth regulator effect on different cancers. Unfortunately, dose-limiting toxicity (hypercalcemia) limits its use in anticancer therapy. For primary liver tumors, loco-regional delivery of 1,25-(OH)2 D3 in lipiodol might avoid high systemic concentrations and development of hypercalcemia. MATERIALS AND METHODS: 1,25-(OH)2 D3 alone or mixed in lipiodol, was delivered at different concentrations into the hepatic artery of rats bearing a primary liver tumor. Calcium levels, tumor volume and proliferation index were assessed after treatment. RESULTS: Serum calcium values were significantly lower when the drug was mixed into lipiodol. Treatment with 10 micrograms of 1,25-(OH)2 D3 in ethanol resulted in a decrease in proliferation index within the tumor. CONCLUSIONS: The delivery of 1,25-(OH)2 D3 mixed in lipiodol reduces the subsequent elevation of serum calcium. Locoregional treatment with 1,25-(OH)2 D3 was shown for the first time to be effective on primary liver tumor growth in vivo.


Asunto(s)
Calcitriol/administración & dosificación , Aceite Yodado/administración & dosificación , Neoplasias Hepáticas Experimentales/tratamiento farmacológico , Animales , Calcio/sangre , División Celular/efectos de los fármacos , Portadores de Fármacos , Inyecciones Intraarteriales , Masculino , Ratas , Ratas Sprague-Dawley , Células Tumorales Cultivadas
16.
Eur J Cardiothorac Surg ; 15(2): 218-20, 1999 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10219560

RESUMEN

Mesenteric ischemia after cardiac surgery is rare but dramatic. We present a patient who had acute mesenteric ischemia following low cardiac output after coronary artery bypass grafting. Our patient was successfully treated with continuous intra-arterial perfusion with papaverine. We think that selective angiography must be performed as early as mesenteric ischemia is suspected, to get earlier diagnosis and treatment of an ischemic patient.


Asunto(s)
Puente de Arteria Coronaria/efectos adversos , Isquemia/etiología , Mesenterio/irrigación sanguínea , Papaverina/uso terapéutico , Vasodilatadores/uso terapéutico , Enfermedad Aguda , Anciano , Angina Inestable/cirugía , Estudios de Seguimiento , Humanos , Infusiones Intraarteriales , Isquemia/diagnóstico por imagen , Isquemia/tratamiento farmacológico , Masculino , Arteria Mesentérica Superior/diagnóstico por imagen , Mesenterio/diagnóstico por imagen , Papaverina/administración & dosificación , Perfusión/métodos , Radiografía , Vasodilatadores/administración & dosificación
17.
N Z Med J ; 112(1084): 91-3, 1999 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-10210294

RESUMEN

AIMS: To outline the role of liver resection in the treatment of colorectal liver metastases, with particular reference to hospital morbidity, mortality and subsequent survival. METHODS: Seventy major liver resections were performed in Wellington by the senior author (RSS) between 1987 and 1997 for colorectal metastases. Fifty-three entailed resection alone with intent to cure, nine were associated with additional cryotherapy and in eight hepatic arterial chemotherapy was subsequently given. Resection was the initial form of liver treatment in all 70 patients. Patients were aged between 29 and 76 years with a median of 60.0 years. All patients were judged pre-operatively to have tumour confined to a resectable portion of the liver. Data were collected prospectively and held in a computerised database. Follow-up was available on all patients. RESULTS: Median operating theatre time was five hours and median blood loss was 1500 mL (60 mL-25 L). Eighty percent of resections entailed four or more liver segments. Postoperative morbidity occurred in 26 (37.1%) and 30-day mortality was 5.7%. Median hospital stay was 11 days (2-67). In the 53 patients who underwent resection alone, the three and five-year actuarial survival rates, including the 30-day mortality, were 62.0% and 27.2%, respectively. Dukes stage of the primary was the only significant prognostic factor found in this subgroup of patients (p<0.05). CONCLUSIONS: Resection of colorectal liver metastases can achieve extension of life and long-term survival in selected patients. However, it remains a major undertaking and is probably best performed in units with appropriate expertise and experience.


Asunto(s)
Neoplasias Colorrectales/patología , Hepatectomía , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Adulto , Anciano , Antineoplásicos/uso terapéutico , Pérdida de Sangre Quirúrgica/estadística & datos numéricos , Terapia Combinada , Crioterapia , Femenino , Hepatectomía/efectos adversos , Hepatectomía/métodos , Hepatectomía/mortalidad , Mortalidad Hospitalaria , Humanos , Infusiones Intraarteriales , Tiempo de Internación/estadística & datos numéricos , Tablas de Vida , Neoplasias Hepáticas/mortalidad , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Análisis de Supervivencia , Resultado del Tratamiento
18.
Surg Laparosc Endosc ; 8(6): 413-5, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9864105

RESUMEN

Dieulafoy's ulcer, accounting for approximately 5% of upper GI bleeding, is best managed by therapeutic endoscopy. Some patients, however, require surgical treatment. Presented here is a case in which the lesion was treated by combined endoscopy and endogastric surgery. To the authors' best knowledge, this is the first published report of such management. This relatively new technique may be offered in suitable cases but should be attempted only by well-trained laparoscopic surgeons.


Asunto(s)
Mucosa Gástrica/patología , Gastroscopía/métodos , Laparoscopía/métodos , Úlcera Péptica Hemorrágica/cirugía , Úlcera Gástrica/cirugía , Adulto , Terapia Combinada , Estudios de Seguimiento , Gastroscopios , Humanos , Laparoscopios , Masculino , Úlcera Péptica Hemorrágica/etiología , Úlcera Gástrica/complicaciones , Resultado del Tratamiento
19.
Arch Anat Cytol Pathol ; 46(3): 178-83, 1998.
Artículo en Francés | MEDLINE | ID: mdl-9754373

RESUMEN

The authors report two cases of pulmonary lymphangioleiomyomatosis which were diagnosed by surgical biopsies. Immunohistochemical study showed positive staining of the smooth muscle cells using antibodies directed against smooth muscle actin, specific muscle actin, HMB45 and vimentin. Ultrastructural study showed some smooth muscle differentiation features, with numerous myofilaments and some dense bodies near the plasma membrane. In one case, the patient was treated by a double-lung transplantation. LAM is a non-familial disease occurring exclusively in females. The etiology is unknown. This disease can be complicated by chronic respiratory failure. Extrapulmonary sites are not rare, particularly in the uterus. Anti-estrogen treatment can slow the course of the disease. Lung transplantation is actually the only effective treatment at the present time therapy. The differential diagnosis of this disease is discussed.


Asunto(s)
Neoplasias Pulmonares/patología , Linfangiomioma/patología , Actinas/análisis , Adulto , Femenino , Humanos , Inmunohistoquímica , Pulmón/patología , Pulmón/ultraestructura , Neoplasias Pulmonares/cirugía , Neoplasias Pulmonares/ultraestructura , Linfangiomioma/cirugía , Linfangiomioma/ultraestructura , Vimentina/análisis
20.
Rev Mal Respir ; 14(1): 59-60, 1997 Jan.
Artículo en Francés | MEDLINE | ID: mdl-9082508

RESUMEN

Pulmonary involvement is very rare in giant cell arteritis. The sign that is most often encountered seems to be dry cough which can remain, for a long time, the sole manifestation of this disease. We report a case of giant cell arteritis in a 66 year old woman that expressed for only symptom a dry cough during one year. A rapid regression of clinical symptoms and radiologic signs have been observed with steroid therapy. Presence of isolated cough along with biological marks of inflammation in a elderly patient should lead to temporal biopsy when no other evidence cause has been found.


Asunto(s)
Tos/etiología , Arteritis de Células Gigantes/complicaciones , Anciano , Biopsia , Enfermedad Crónica , Tos/diagnóstico por imagen , Femenino , Arteritis de Células Gigantes/patología , Humanos , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA